-Reuters
Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2
Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.
Related Posts
Jack In The Box Stock Gains Post Q3 Top-Line Beat
Jack In The Box Inc (NASDAQ:JACK) reported third-quarter FY22 sales growth of 47.8% year-on-year to $398.31 million, beating the consensus of…
UBS Group Fro Q2 Expect A Low-To-Mid Single-Digit Decline In Net Interest Income In Global Wealth Management; Mid-To-High Single-Digit Decrease In Net Interest Income In Personal & Corporate Banking
OutlookAlthough monetary easing is expected in the Eurozone, the US and Switzerland, the timing and magnitude of rate cuts by central banks are unclear, as inflation remains above their target range. In addition, the
Vertex Energy Sees Q3 Throughput Volumes Better Than Guidance, Thanks To Optimisation Initiatives
Vertex Energy Inc (NASDAQ: VTNR) updated its financial